Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischemic stroke (Cochrane review)

Stroke. 2002 Jul;33(7):1925-6. doi: 10.1161/01.str.0000018820.99077.46.
No abstract available

Publication types

  • Comparative Study
  • Meta-Analysis

MeSH terms

  • Acute Disease
  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use*
  • Brain Ischemia / complications
  • Brain Ischemia / drug therapy*
  • Chondroitin Sulfates / adverse effects
  • Chondroitin Sulfates / therapeutic use
  • Databases, Factual
  • Dermatan Sulfate / adverse effects
  • Dermatan Sulfate / therapeutic use
  • Drug Combinations
  • Enoxaparin / adverse effects
  • Enoxaparin / therapeutic use
  • Heparin / adverse effects
  • Heparin / therapeutic use*
  • Heparin, Low-Molecular-Weight / adverse effects
  • Heparin, Low-Molecular-Weight / therapeutic use*
  • Heparinoids / adverse effects
  • Heparinoids / therapeutic use*
  • Heparitin Sulfate / adverse effects
  • Heparitin Sulfate / therapeutic use
  • Humans
  • Odds Ratio
  • Pulmonary Embolism / prevention & control
  • Randomized Controlled Trials as Topic / statistics & numerical data
  • Stroke / complications
  • Stroke / drug therapy*
  • Treatment Outcome
  • Venous Thrombosis / prevention & control

Substances

  • Anticoagulants
  • Drug Combinations
  • Enoxaparin
  • Heparin, Low-Molecular-Weight
  • Heparinoids
  • Dermatan Sulfate
  • Heparin
  • Chondroitin Sulfates
  • Heparitin Sulfate
  • danaparoid